Lytix Biopharma ASA (OSL:LYTIX)

Revenue by Segment

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Biotechnology (Startups)		11.13M	3.99M	11.03M	19.31M	4.07M
Biotechnology (Startups) Growth		178.98%	-63.82%	-42.87%	373.91%	-35.73%
Total		11.13M	3.99M	11.03M	19.31M	4.07M
Total Growth		178.98%	-63.82%	-42.87%	373.91%	-35.73%

Revenue by Geography

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
US		11.13M	3.99M	11.03M	19.29M	-
US Growth		178.98%	-63.82%	-42.81%	-	-
Norway		-	-	-	17.00K	4.07M
Norway Growth		-	-	-	-99.58%	-35.73%
Total		11.13M	3.99M	11.03M	19.31M	4.07M
Total Growth		178.98%	-63.82%	-42.87%	373.91%	-35.73%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 12, 2026

Data Sources Report a data error